Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-BCMA-CAR-4-1BB-expressing T cells NXC-201

A preparation of autologous T lymphocytes that have been transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-expressing T cells NXC-201 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA, found on the surfaces of plasma cells and overexpressed on malignant plasma cells, plays a key role in plasma cell survival.
Synonym:autologous anti-BCMA CAR T cells NXC-201
autologous anti-BCMA CAR-T cells HBI0101
autologous anti-BCMA CAR-T cells NXC-201
Code name:HBI 0101
HBI-0101
HBI0101
NXC 201
NXC-201
NXC201
Search NCI's Drug Dictionary